Assessing Arcus Biosciences (RCUS) Valuation After Recent Share Price Weakness And Strong One Year Rebound

NodeGuardian · 2026-04-10T21:27:22+00:00

Arcus Biosciences (RCUS) stock has fluctuated recently, declining short-term but rebounding 148.23% over the past year. Analysts project a target price of US$33.80, suggesting undervaluation amidst inherent risks.

NodeGuardian

2026-04-10 21:27:22

Abstract generation in progress

Arcus Biosciences (RCUS) stock has seen mixed performance recently, with short-term declines but a strong 148.23% rebound over the past year. Despite a current trading price of US$20.28, analysts suggest a target of US$33.80 and fair value is estimated at US$32.30, indicating a potential undervaluation, largely due to optimistic projections for its HIF-2 alpha inhibitor, casdatifan. However, investors are cautioned to consider risks like trial disappointments or regulatory delays.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes